1 / 30

Adi pose Tissue Inflammation in the Etiology of Obesity-Associated Chronic Disease

Adi pose Tissue Inflammation in the Etiology of Obesity-Associated Chronic Disease. Mario Kratz, Ph.D . Associate Member, Fred Hutchinson Cancer Research Center Public Health Sciences, Cancer Prevention Program Research Assistant Professor , University of Washington

chip
Download Presentation

Adi pose Tissue Inflammation in the Etiology of Obesity-Associated Chronic Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Adipose Tissue Inflammation in the Etiology of Obesity-AssociatedChronic Disease Mario Kratz, Ph.D. Associate Member, Fred Hutchinson Cancer Research Center Public Health Sciences, Cancer Prevention Program Research Assistant Professor, University of Washington Departments of Epidemiology & Medicine WHI Diabetes/Obesity Scientific Interest Group June 19, 2014

  2. Overview Obesity Type 2Diabetes Low-grade chronic inflammation Diet

  3. Overview Obesity Insulinresistance Type 2Diabetes Low-grade chronic inflammation Beta-celldysfunction ? Diet

  4. Overview Obesity Insulinresistance Type 2Diabetes Low-grade chronic inflammation Beta-celldysfunction ? Diet

  5. Overview IDEA-studyCROSSROADS Obesity Insulinresistance Type 2Diabetes Low-grade chronic inflammation Beta-celldysfunction ? Diet

  6. Background “Old” Paradigm: the relationship between obesity, adipose tissue inflammation, and insulin resistance. Lumeng et al.; JCI 2007; 117: 175-84

  7. Background “Old” Paradigm: the relationship between obesity, adipose tissue inflammation, and insulin resistance. Lumeng et al.; JCI 2007; 117: 175-84

  8. Background “Old” Paradigm: the relationship between obesity, adipose tissue inflammation, and insulin resistance. - Adiponectin + Lumeng et al.; JCI 2007; 117: 175-84

  9. Background “Old” Paradigm: the relationship between obesity, adipose tissue inflammation, and insulin resistance. CD11c+ - Adiponectin + Lumeng et al.; JCI 2007; 117: 175-84

  10. Background Uysal et al.; Nature 1997; 389: 610-4Kanda et al.; JCI 2006; 116: 1494-1505Arkan et al.; Nat Med 2005; 11: 191-8 Orr et al.; Diabetes 2012; 61: 2718-27McGillicuddy et al.; Diabetes 2011; 60: 1688-98Weisberg et al.; JCI 2006; 116: 115-24

  11. Background Uysal et al.; Nature 1997; 389: 610-4Kanda et al.; JCI 2006; 116: 1494-1505Arkan et al.; Nat Med 2005; 11: 191-8 Orr et al.; Diabetes 2012; 61: 2718-27McGillicuddy et al.; Diabetes 2011; 60: 1688-98Weisberg et al.; JCI 2006; 116: 115-24

  12. Background TNF alpha IL-1 beta MCP-1 CCR2 TLR4 CD11c Uysal et al.; Nature 1997; 389: 610-4Kanda et al.; JCI 2006; 116: 1494-1505Arkan et al.; Nat Med 2005; 11: 191-8 Orr et al.; Diabetes 2012; 61: 2718-27McGillicuddy et al.; Diabetes 2011; 60: 1688-98Weisberg et al.; JCI 2006; 116: 115-24Patsouris et al.; Cell Metab 2008; 8: 301-9

  13. Background - Summary • ‘Old’ paradigm: • Increased adiposity causes adipose tissue inflammation, which is the major cause for obesity-associated insulin resistance • The assumption was that an (unknown) pro-inflammatory trigger in adipose tissue causes macrophages to switch to a classically activated (“M1”) phenotype and causes the clonal expansion of Th1 T-cells and cytotoxic T-cells • “M1” macrophages, Th1 T-cells, and cytotoxic T-cells are the major producers of pro-inflammatory cytokines (TNFalpha, IL-1beta, IL-6, IFNgamma) • Adipose tissue inflammation = “bad”Reduction in inflammation = “good”

  14. Objectives of this presentation • Assess the relationship between adiposity, adipose tissue inflammation, and insulin resistance in humans: • Cross-sectionally in a group of individuals varying widely in adiposity • Longitudinally as body weight and metabolic health change substantially after bariatric surgery

  15. METHODS Snap-freeze whole tissue for gene expressionanalysis (qPCR) Adipose tissue Collagenase digestion Adipocytes Stromavascular cells (SVC) C Antibody Flow cytometry

  16. METHODS

  17. Obesity, Adipose Tissue Inflammation, and Insulin Resistance in Humans Individuals with chronic inflammatory conditions or those takinganti-inflammatory or anti-diabetic drugs were excluded.

  18. Obesity & Adipose Tissue Inflammation in HumansCross-sectional associations Association between BMI and adipose tissue inflammation inhumans is rather weak. Is inflammation more closely associated with disease than BMI!?

  19. CROSSROADS • Calorie Reduction Or Surgery: Seeking Remission for Obesity And DiabeteS (PIs: D. Cummings, D. Flum, UW) • Aims: • Establish the feasibility of novel methods to recruit an appropriate cohort for a RCT of gastric bypass surgery vs. best medical/lifestyle care to treat T2DM and obesity. • Conduct a pilot RCT of gastric bypass surgery vs. intensive lifestyle intervention of T2DM and obesity in patients with T2DM and a BMI of 30 to 40 kg/m2 • Explore the effects of RYGB vs. non-surgical weight loss on low-grade chronic adipose tissue inflammation clinicaltrials.gov registration number: NCT01295229

  20. CROSSROADS – Study Design

  21. CROSSROADS – Subjects

  22. CROSSROADS – Results

  23. CROSSROADS – Results

  24. CROSSROADS – Results

  25. CROSSROADS – Results

  26. CROSSROADS – Conclusions • As expected, insulin sensitivity and glucose tolerance improved more after gastric bypass surgery than after similar weight loss induced by an intensive lifestyle intervention. • Improvements in insulin sensitivity and glucose tolerance after gastric bypass were not associated with a resolution of adipose tissue inflammation. • Some measures of inflammation (adipose tissue IL-1beta expression, numbers of neutrophil granulocytes) increased to a similar extend with weight loss in both groups. • Exactly the same result in a second longitudinal study of the relationship between adipose tissue inflammation and insulin resistance in individuals following bariatric surgery (follow-up at ~4 weeks and 6-12 months after surgery)

  27. Conclusions • The lack of a reduction in adipose tissue inflammation associated with substantial improvements in glucose tolerance following bariatric surgery could be explained by: • A dissociation of the relationship between adipose tissue inflammation and insulin resistance • A shift towards non insulin-dependent modes of glucose uptake, i.e. increased glucose effectiveness. If this were the case, then the inflammation-insulin resistance link may not be affected by bariatric surgery, but may become less relevant for glucose homeostasis. Schwartz et al.; Nature 2013; 503: 59-66 Ryan et al.; Nature 2014; 509: 183-8

  28. Why was adipose tissue inflammation not reduced with weight loss (even substantial weight loss ~12 months after bariatric surgery)?

  29. Emerging paradigm • Immune cells in adipose tissue play major roles in maintaining tissue homeostasis • Role in angiogenesis • Role in adipose tissue expansion and remodeling • Role as a buffer for excess lipid • The activation and pro-inflammatory activity may be an indirect consequence of these physiological functions. • Macrophages in human adipose tissue are not classically activated “M1” cells. • Hypothesis: adipose tissue macrophages may acquire a pro-inflammatory phenotype due to exposure to free fatty acids. • Much less clear if adipose tissue inflammation = bad. While low-grade chronic inflammation likely is a major cause of insulin resistance, lack of an appropriate immune response to pro-inflammatory stimuli may have more severe health consequences. Xu et al.; Cell Metab. 2013; 18: 816-30 Wernstedt-Asterholm et al.; Cell Metab. 2014; 20: 1-16

  30. Acknowledgements FHCRC: • Derek Hagman, Ph.D., M.P.H. • Ilona Larson, Ph.D. • Gail Cromer, M.S. • Jessica Kuzma, M.S. • Karen Makar, Ph.D. • Xiaoling Song, Ph.D. • Staff of the Prevention Center • Staff of the Flow Cytometry Shared Resource Group Health Research Institute: • David Arterburn, M.D., M.P.H. University of Chicago: • Lev Becker, Ph.D. University of Washington: • David Cummings, M.D. • David Flum, M.D., M.P.H. • Karen Foster-Schubert, M.D. • Brian van Yserloo, B.S. • Staff of the Clinical Research Center Puget Sound Surgical Center, Edmonds, WA: • Peter Billing, M.D. • Rob Landerholm, M.D. • Matt Crouthamel, M.D. ADA Clinical/Translational Research Award 7-09-CT-36 (PI: Kratz)NCI R21CA143248 (PI: Kratz)NIDDK R01 DK089528 (PI: Cummings / Flum)

More Related